Kiora Pharmaceuticals, Inc. Common Stock (KPRX) is a publicly traded Healthcare sector company. As of May 21, 2026, KPRX trades at $2.64 with a market cap of $11.12M and a P/E ratio of -1.01. KPRX moved +0.40% today. Year to date, KPRX is +25.71%; over the trailing twelve months it is -15.33%. Its 52-week range spans $1.76 to $4.18. Analyst consensus is buy with an average price target of $12.00. Rallies surfaces KPRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Kiora Reports No Serious Adverse Events in Phase 1 KIO-301 Study, Initiates Phase 2 Trial: Kiora published peer-reviewed findings from its Phase 1 ABACUS-1 study of KIO-301 in retinitis pigmentosa, showing no serious adverse events or dose-limiting toxicities across six participants over 30 days. The company has launched the randomized Phase 2 ABACUS-2 trial evaluating higher doses for functional vision improvements.
| Metric | Value |
|---|---|
| Price | $2.64 |
| Market Cap | $11.12M |
| P/E Ratio | -1.01 |
| EPS | $-2.60 |
| Dividend Yield | 0.00% |
| 52-Week High | $4.18 |
| 52-Week Low | $1.76 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-10.84M |
| Gross Margin | 0.00% |
1 analysts cover KPRX: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $12.00.